UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 55

Sortiert nach

Histone‐Specific CD4+ T Cell Plasticity in Active and Quiescent Systemic Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2024-05, Vol.76 (5), p.739-750

2024

Volltextzugriff (PDF)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

Arthritis research & therapy, 2019-02, Vol.21 (1), p.54-54, Article 54

2019

Volltextzugriff (PDF)

Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab

Seminars in arthritis and rheumatism, 2015-08, Vol.45 (1), p.48-54

2015

Volltextzugriff (PDF)

Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response

Frontiers in pharmacology, 2019-04, Vol.10, p.296-296

2019

Volltextzugriff (PDF)

Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study

Clinical rheumatology, 2021-06, Vol.40 (6), p.2251-2262

2021

Volltextzugriff (PDF)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

Arthritis research & therapy, 2019-02, Vol.21 (1), p.69-69, Article 69

2019

Volltextzugriff (PDF)

Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India

Diagnostics (Basel), 2022-12, Vol.12 (12), p.3102

2022

Volltextzugriff (PDF)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)

Frontiers in medicine, 2021-09, Vol.8, p.723506-723506

2021

Volltextzugriff (PDF)

18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu’s arteritis

European journal of nuclear medicine and molecular imaging, 2017-07, Vol.44 (7), p.1109-1118

2017

Volltextzugriff (PDF)

Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey

Frontiers in medicine, 2022-05, Vol.9, p.833139-833139

2022

Volltextzugriff (PDF)

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

Clinical immunology communications, 2022-12, Vol.2, p.23-29

2022

Volltextzugriff (PDF)

Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis

Seminars in arthritis and rheumatism, 2020-06, Vol.50 (3), p.509-514

2020

Volltextzugriff (PDF)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

European journal of internal medicine, 2020-06, Vol.76, p.43-49

2020

Volltextzugriff (PDF)

Drug retention rates of biological agents in adult onset Still's disease

Seminars in arthritis and rheumatism, 2021-02, Vol.51 (1), p.1-6

2021

Volltextzugriff (PDF)

The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort

Rheumatology (Oxford, England), 2024-02, Vol.63 (2), p.e39-e42

2024

Volltextzugriff (PDF)

Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients

Rheumatology (Oxford, England), 2021-01, Vol.60 (1), p.465-467

2021

Volltextzugriff (PDF)

Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2016-08, Vol.75 (8), p.1511-1520

2016

Volltextzugriff (PDF)

357. EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE

Rheumatology (Oxford, England), 2019-03, Vol.58 (Supplement_2)

2019

Volltextzugriff (PDF)

288. DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASU’S ARTERITIS: A SINGLE-CENTER EXPERIENCE

Rheumatology (Oxford, England), 2019-03, Vol.58 (Supplement_2)

2019

Volltextzugriff (PDF)

Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease

European journal of internal medicine, 2020-04, Vol.74, p.92-98

2020

Volltextzugriff (PDF)

Prevalence of Takayasu arteritis in young women with acute ischemic heart disease

International journal of cardiology, 2018-02, Vol.252, p.21-23

2018

Volltextzugriff (PDF)

CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade

Arthritis & rheumatology (Hoboken, N.J.), 2020-04, Vol.72 (4), p.565-575

2020

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)

Publikationsform

Artikel
(53)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Histone‐Specific CD4+ T Cell Plasticity in Active and Quiescent Systemic Lupus Erythematosus

Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

Interleukin-6 in ANCA-associated vasculitis: Rationale for successful treatment with tocilizumab

Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production

Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response

Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease

An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes

FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is Not Specific for Active Disease

Impact of Geographic Location on Diagnosis and Initial Management of Takayasu Arteritis: A Tale of Two Cohorts from Italy and India

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)

18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasu’s arteritis

Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey

Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis

Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

Drug retention rates of biological agents in adult onset Still's disease

The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort

Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients

Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis

357. EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE

288. DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASU’S ARTERITIS: A SINGLE-CENTER EXPERIENCE

Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease

Prevalence of Takayasu arteritis in young women with acute ischemic heart disease

CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade

Aktive Filter

Suchergebnisse filtern